Piper Sandler initiated coverage of Merus (MRUS) with an Overweight rating and $84 price target The firm views the company’s EGFRxLGR5 bispecific, petosemtamab, as “significantly de-risked ...

Merus Shares Are Up Today: What's Going On? Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted ...

One thing we could say about the analysts on Merus N.V. (NASDAQ:MRUS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...

Merus N.V. announced progress on its clinical trials involving petosemtamab, designed for treating recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal ...

Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Merus (MRUS – Research Report) today and set a price target of $93.00. The company’s shares closed yesterday at $46.22.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company ...

Merus (NASDAQ:MRUS – Get Free Report) saw a large drop in short interest in the month of February.As of February 15th, there was short interest totalling 6,640,000 shares, a drop of 13.5% from ...

Dutch biopharma Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy for cancer. Bizengri (zenocutuzumab) targets the ...

In September 2024, Merus announced the first patient was dosed in LiGeR-HN1, a phase 3 trial evaluating the efficacy and safety of petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m ...